Advancements in the identification of EV derived mRNA biomarkers for liquid biopsy of clear cell renal cell carcinomas


Posted: 2021-11-18 20:00:00
Objective: To propose EV-derived mRNA as a potential diagnostic biomarker detecting the presence of clear cell renal cell carcinoma (ccRCC). There is currently no kidney cancer specific screening or diagnostic technology. Therefore, one-third of kidney cancer diagnoses occur after the cancer has metastasized and is past curative measures MATERIALS AND METHODS: Urine, plasma, normal tumor adjacent tissue, and tumor tissue was collected from a limited population of ccRCC patients. Extracellular vesicle (EV) isolation was performed on each sample, followed by mRNA extraction from isolated EVs. NanoString® nCounter technology was utilized to count the mRNA transcripts present in matched plasma, urine, tumor tissue, and normal tumor adjacent tissue samples. Results: 770 mRNA transcripts related to gene's affecting cancer's progression and metastasis processes were evaluated. Four EV derived mRNA transcripts (ALOX5, RBL2, VEGFA, TLK2) were found specific to urine and cancer tissue samples. Conclusion: Four candidate RCC-specific urine EV biomarkers were identified. However, due to the lack of a true negative control and urine collection techniques, further re-examination is necessary for validation. This study demonstrates the promise of defining disease-specific EV biomarkers in liquid biopsy patient samples. Keywords: biomarker; clear cell renal cell carcinoma; extracellular vesicles; liquid biopsy; renal cell carcinoma.

参考サイト PubMed: exsome



バイオクイックニュース日本語版:エクソソーム特集

バイオクイックニュース日本語版
10月 16, 2019 バイオアソシエイツ

南カリフォルニアのHOAG 病院は、癌の遺伝的リスクが高い人の癌検出と管理の早期疾患マーカーとしてエクソソームを研究。

カリフォルニア州オレンジ郡にある非営利の地域医療提供ネットワークのHoag Memorial Hospital Presbyterianは、癌診断、癌の進行、および治療抵抗性の初期疾患マーカーの可能性を特定および特徴付ける研究の開始を発表した。 Exosome Sciences社および、Aethlon Medical社の子会社との提携により、癌の遺伝的リスクが高い癌患者の エクソソーム 研究を開始する。…

ゲスト 625人 と メンバー 6人 がオンラインです